ShareValue.ai

ShareValue scores for 9996.HK: Valuation 49, Quality 40, Growth 61, Health 44.

9996.HK
HKEX

Peijia Medical Ltd

HK$3.77(-6.22%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

6% to 17%
Valuation
49
Fair Value
Price vs Value
Quality
40
Moderate
Business Strength
Growth
61
Moderate
Revenue & Earnings
Health
44
Moderate
Financial Stability
Momentum
12
Bearish
Price Trend

Company Details

About

Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People's Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company's products include transcatheter aortic valve replacement (TAVR) systems, crosslinked dry-tissue and polymeric tri leaflet TAVR systems, transcatheter aortic valve systems, lithotripsy valvuloplasty technology and interventional robotics technology, transseptal mitral valve replacement systems, transfemoral balloon catheter, introducer sheath, pre-shaped guidewire, detachable coils, balloon guide catheter, aspiration catheter, stent retriever, delivery balloon dilatation catheter, balloon dilatation catheter, microcatheter, micro guidewire, micro guidewire, guide catheter, distal access guide catheter, intermediate catheter, and power supply. In addition, it engages in the trading and holding business. Peijia Medical Limited was incorporated in 2012 and is headquartered in Suzhou, the People's Republic of China.

Score Analysis

AI Investment Thesis

Data as of:Jun 29, 2026
|
Last calculated:Jun 29, 2026